Therefore, targeting the interaction between WDR5 and MLL1 to inhibit the MLL1 activity of catalyzing H3K4me3 is a potential effective therapeutic strategy for ALL and AML [16,17]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.